Ophthalmology · GlaucomaRegulatory Approvalcommercialnear-term

FDA Grants AP Status for Dorzolamide Hydrochloride ANDA205294

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/21/2026, 6:31:37 PM

Assessment confidence: 40% · The main uncertainty is whether medium-relevance evidence fully captures sub-indication-specific dynamics.

Executive Thesis

The FDA's grant of Abbreviated Approval for a generic version of Dorzolamide Hydrochloride by FDC LTD introduces significant competitive pressure in the glaucoma treatment market. This could lead to pricing changes and market share shifts for existing branded products, necessitating close monitoring by portfolio teams. Regulatory context from FDA (FDA AP — DORZOLAMIDE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 2 ranked evidence items (0 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this new generic on pricing and market share for existing branded products in the glaucoma category. The strongest clinical anchor is A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. In ophthalmology, 1 regulatory and 1 competitive items passed relevance filtering for FDC LTD.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for Pfizer's Marstacimab (HYMPAVZI) Supplement (Humanexa Signals) — sponsor/company relevance (pfizer). This approval allows FDC LTD to enter the market with a generic version of Dorzolamide Hydrochloride, potentially increasing competition in the glaucoma treatment space.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DORZOLAMIDE HYDROCHLORIDE (SUPPL) (FDA). Entity match (fdc ltd); Regulatory pathway relevance (nda). The approval signifies compliance with FDA standards but does not indicate any changes to existing regulatory frameworks for other products.

Key Opportunities

The entry of a generic competitor may erode the market share and pricing power of established brands in the glaucoma category, impacting revenue streams.
Portfolio teams should assess the impact of this new generic on pricing and market share for existing branded products in the glaucoma category.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timing and pricing strategies of FDC LTD post-approval.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DORZOLAMIDE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (fdc ltd); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HYDROXYZINE HYDROCHLORIDE (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — VALACYCLOVIR HYDROCHLORIDE (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CYCLOBENZAPRINE HYDROCHLORIDE (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source

A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Cognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Status Epilepticus Population Study (STEPS)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effect of MEMOPTIC on Visual Field of Patients Followed for Chronic Open-angle Glaucoma
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Grants Priority Review for Pfizer's Marstacimab (HYMPAVZI) Supplement
Humanexa Signalsmedium relevance
Sponsor/company relevance (Pfizer)
FDA Grants Approval for Tofacitinib Citrate ANDA218900 by Saptalis Pharmaceuticals
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Oro-esophageal feeding for tracheostomized patients with severe traumatic brain injury: a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

FDC LTD
Dorzolamide Hydrochloride
glaucoma treatment market

Commercial impact

medium

The entry of a generic competitor may erode the market share and pricing power of established brands in the glaucoma category, impacting revenue streams.

Regulatory impact

low

The approval signifies compliance with FDA standards but does not indicate any changes to existing regulatory frameworks for other products.

What to watch

Monitor market entry timing and pricing strategies of FDC LTD post-approval.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.